The approval is the 14 th for Keytruda, extending its use into a tenth ... for Opdivo in second-line HCC after it became clear the EMA would not accept the data that backed its US approval.

It was more successful in Europe, where Merck is known as MSD, as the EMA gave the go-ahead for ... application in the US across all of Keytruda’s approved indications in adults, both on its ...

Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

UBS Group AG said it received regulatory approval to sell a 36% stake in Credit Suisse’s China venture, bringing closer the full integration of the two banks in the world’s second-largest economy.

ByInvesting.com • Sep 28, 2023 Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA Plus LENVIMA ... today announced that the European Medicines Agency’s Committee ...

The trial’s first phase will begin in university hospitals across the Netherlands, Denmark, Germany and Sweden.

and positive safety profile - - Systemic ORR and complete response rates meaningfully higher thus far than historical Keytruda® monotherapy data in interim read out of a combination trial of ...

For drugs not yet approved in any EU Member State, allowing manufacturers to apply for authorisation in multiple EU countries at the same time. With offices across the EU, Proregulations can ...

FEMA approved Michigan’s request for a federal disaster declaration after a series of floods devastated the Detroit area in August 2023. The disaster declaration allowed residents to apply for ...

“FDA approval of our forthcoming U.S. trials in ... recruited in a combination trial of Alpha DaRT with pembrolizumab (Keytruda), a checkpoint inhibitor, in treating patients with recurrent ...

A pembrolizumab (Keytruda) combination led to an overall survival (OS) boost in patients with newly diagnosed, previously ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today an ...